glp-1 ra medications New Guidelines for Type 2 Diabetes in 2025 GLP-1 drugs are revolutionizing the

Studies that include patients who are considered at-risk (i.e., diabetics, cardiac, elderly, etc.) and are currently taking GLP-1 RAs should also be performed as these patients may have compounding risk during the perioperative period which may make them more susceptible to complications related to GLP-1 use (Santos et al

In 2005, exenatide received FDA approval to treat diabetes under the name Byetta

However, a low-calorie diet along with GLP-1 agonist drugs can also lead to loss of lean mass, emphasizing the need for protein intake with resistance training to preserve muscle mass

This is particularly important with tirzepatide, which can reduce oral contraceptive exposure during initiation and dose escalation, potentially requiring backup contraception

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm2016: executive summary